NICE set to approve trastuzumab emtansine for breast cancer

NHS England will routinely fund Kadcyla for people with advanced HER-2 positive cancer Related items fromOnMedica Ovarian cancer drug may help stall breast cancer The medicine price debate Breast cancer drug ‘too costly’ for NHS Experts recommend anastrozole for postmenopausal women with family history of breast cancer Cancer-preventing drugs
Source: OnMedica Latest News - Category: UK Health Source Type: news

Related Links:

The objective of this study is to assess the mutational spectrum of 14 additional FA genes (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCP, FANCQ, FANCR and FANCU) in a cohort of hereditary cancer patients, to compare with local cancer-free controls as well as GnomAD. A total of 1021 hereditary cancer patients and 194 controls were analyzed using our next generation custom sequencing panel. We identified 35 pathogenic variants in eight genes. A significant association with the risk of breast cancer/breast and ovarian cancer was found for carriers of FANCA mutations (odds ratio (OR) = 3.14 95% ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractGenetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and have emerged as promising anticancer therapies, especially in tumors harboring deleterious germline or somatic breast cancer susceptibility gene (BRCA) mutations. However, the utility of PARP inhibitors could be expanded beyond germlineBRCA1/2 mutated cancers by causing DNA damage with cytotoxic agents in the presence of a DNA repair inhibitor. US Food and Drug Admin...
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
ConclusionsWhile the summary measures indicate no significant differences in AMH levels betweenBRCA1/2+ cases and controls, readers should be aware that there are significant methodological differences in the AMH reports. Additionally, the response to COH protocols does not seem to be significantly lower inBRCA1/2 mutation carriers in the existing literature. Continued research on both of these clinical parameters would be beneficial for patient counseling.
Source: Journal of Assisted Reproduction and Genetics - Category: Reproduction Medicine Source Type: research
AbstractWith the increased rate of stable remission after gonadotoxic cancer treatment, new methods of fertility preservation are required in order to provide the best possible care for oncological patients. Here, we report an original case of euploid blastocyst cryopreservation after in vitro maturation of ovarian tissue oocytes (OTO IVM). Thirty-three oocytes were obtained from the ovarian tissue after ovariectomy in the breast cancer patient. Six out of 12 matured oocytes fertilized successfully and 3 blastocysts were formed. Genetic investigation for mutations associated with this type of malignancy found that the pati...
Source: Journal of Assisted Reproduction and Genetics - Category: Reproduction Medicine Source Type: research
Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context's lead new drug candidate. That experimental therapy, called onapristone ER, is being evaluated in mid-stage clinical testing in patients with certain types of ovarian and endometrial cancers. Context plans to conduct mid-stage clinical testing of onapristone ER in patients with breast cancer later this year. Financial…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
AbstractPurposeTo examine trends, characteristics and outcomes of women who develop both ovarian and breast cancers.MethodsThis is a retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1973 to 2013. Among ovarian cancer (n = 133,149) and breast cancer (n = 1,143,219) cohorts, women with both diagnoses were identified and temporal trends, tumor characteristics and survival were examined.ResultsThere were 6446 women with both malignancies, representing 4.8% of the ovarian cancer cohort and 0.6% of the breast cancer cohort. Women with ovarian cancer who had se...
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
Conditions:   Metastatic Breast Cancer;   Recurrent Ovarian Carcinoma Interventions:   Drug: Ribociclib;   Drug: Belinostat Sponsors:   University of Utah;   Novartis;   Acrotech Biopharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Breast Cancer;   Recurrent Ovarian Carcinoma Interventions:   Drug: Ribociclib;   Drug: Belinostat Sponsors:   University of Utah;   Novartis;   Acrotech Biopharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Breast Cancer;   Recurrent Ovarian Carcinoma Interventions:   Drug: Ribociclib;   Drug: Belinostat Sponsors:   University of Utah;   Novartis;   Acrotech Biopharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Herceptin | National Institute for Health and Clinical Excelle | Ovarian Cancer | Ovaries | UK Health | Women